Abstract: The present invention relates to thiophene derivatives represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof, which has TNF-? production suppressive activity and hematologic cancer cell proliferation inhibitory activity, and is useful for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, and further, hematologic cancer.

Abstract: The present invention relates to thiophene derivatives represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof, which has TNF-? production suppressive activity and hematologic cancer cell proliferation inhibitory activity, and is useful for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, and further, hematologic cancer.

Abstract: The invention provides a composition for transdermal or transmucosal administration useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or to treat drug dependence. The composition has an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin or mucous membrane. The composition enables its active ingredient to stably arrive in a sufficient effective amount through the skin and mucous membrane to the body or brain. The composition is free of disadvantages such as a reduction in an active component caused by a first pass effect in the liver, as well as pain, damage or infection.

Abstract: There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

Abstract: There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

Abstract: There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

Abstract: The present invention provides a composition for transdermal or transmucosal administration, which is useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or a therapeutic agent for drug dependence.

Abstract: There are provided a process for preparing an optically active aminopentane derivative that is promising as a psychotropic agent, an antidepressant agent, an antiparkinsonian agent, an anti-Alzheimer's agent, an apoptosis inhibitor, or the like; a novel optically active intermediate oxathiazolidine derivative very useful in the production of the aminopentane derivative; and process for the production thereof. The optically active aminopentane derivatives can be produced in an industrially advantageous manner from a novel optically active oxathiazolidine derivative represented by formula (5): wherein * indicates the position of an asymmetric carbon atom in the R or S configuration, and n is 0 or 1.

Abstract: The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical composition of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.

Abstract: This invention relates to therapeutic agents for diabetes comprising a 2-(N-cyanoimino)thiazolidine-4-one derivatives represented by formula I or a solvate or a pharmaceutically acceptable salt thereof as an active ingredient: wherein ring A represents a benzene ring, a condensed ring, or a heterocyclic ring, each of which may be substituted by one or more substituents selected from a straight or branched C1-C4 alkyl group, a haloalkyl group, a halogen atom or —OR5, R1 represents a single bond, an oxygen atom, a sulfur atom, a methyne group, a straight or branched C1-C4 alkylene or alkenylene group optionally substituted by a phenyl group, R6—X, X—R6, X—R6—X, R6—X—R6, —C(═O)—NR7— or —NR7—C(═O)—, R2 and R3 are the same or different and each represents a hydrogen atom, a C1-C4 alkyl group, —OR8 or a halogen atom, R4 represents a hydrogen atom or a C1-C4 alkyl group, R5 represents a hydrogen atom o

Abstract: This invention relates to therapeutic agents for diabetes comprising a 2-(N-cyanoimino)thiazolidine-4-one derivatives represented by formula I or a solvate or a pharmaceutically acceptable salt thereof as an active ingredient: 1

Abstract: This invention provides novel 2-(N-cyanoimino)thiazolidin-4-one derivatives represented by formula I or a pharmaceutically acceptable salt or solvate thereof: wherein ring A represents a benzene ring, a condensed ring or a heterocyclic ring, each of which may be substituted by one or more substituents selected from a straight or branched C1-C4 alkyl group, a haloalkyl group, a halogen atom or —OR5, R1 represents a single bond, an oxygen atom, a sulfur atom, a methyne group, a straight or branched C1-C4 alkylene or alkenylene group optionally substituted by a phenyl group, R6—X, X—R6, X—R6—X, R6—X—R6, —C(═O)—NR7— or —NR7—C(═O)—, R2 and R3 are the same or different and each represents a hydrogen atom, a C1-C4 alkyl group, —OR8 or a halogen atom, R4 represents a hydrogen atom or a C1-C4 alkyl group, R5 represents a hydrogen atom or a C1-C4 alkyl group, R6 represents a straight or branched C1-C4 al

Abstract: A class of novenl compounds represented by the formula (I) ##STR1## wherein R.sub.1 s are the same or different groups and each represents hydrogen atom or alkyl group having 1 to 4 carbon atoms; R.sub.2 is phenyl group, naphthyl group, or either phenyl or naphthyl substituted with at least one hydroxyl, alkyl having 1 to 4 carbon atoms or alkoxy having 1 to 4 carbon atoms; R.sub.3 is hydrogen atom, alkyl group having 1 to 4 carbon atoms or CH.sub.2 COOR.sub.4 group, in which R.sub.4 is hydrogen atom or alkyl group having 1 to 12 carbon atoms; n is 0 or 1, the configuration of 5-methylene group includes both E-isomer and Z-isomer, providing excepting the case wherein R.sub.1 is hydrogen or methyl, R.sub.2 is 3,5-di-t-butyl-4-hydroxyphenyl, R.sub.3 is hydrogen and n is 0 or pharmacologically acceptable salts thereof when R.sub.3 or R.sub.4 is hydrogen atomThe invention also concerns preparation methods thereof.

Abstract: There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ion

Abstract: A sample having a specific optical path length of 1 to 15 mm is irradiated with near infrared of two or more wavelengths selected from 700 to 1200 nm to determine constituents of dairy products. Preferably, a pair of specific wavelengths comprise a first wavelength having a high correlation with a target constituent and a second wavelength having a low correlation with the target constituent or comprise wavelengths both having high correlations with the target constitutent. Quantities of near infrared of these two specific wavelengths transmitted by the sample are measured to determine absorbencies and a multiple linear regression equation is used to calculate the constituent on the basis of the absorbencies.